FDA drops black-box warning on menopause hormone therapy, sparking debate for breast cancer survivors
The FDA removed the black-box alert on menopausal hormone therapy in November 2025, prompting clinicians to reassess its use, especially for women who have survived breast cancer.
Prescriptions for menopausal hormone therapy fell sharply after the Women’s Health Initiative reported higher breast-cancer rates, but critics have highlighted the study’s focus on older women and outdated progesterone formulations. Subsequent trials, including HABITS and the Stockholm study, produced mixed results and were halted early, leaving no definitive answer. In November 2025 the FDA eliminated the black-box warning, signaling that the risk profile may be more nuanced.
Gynecologists now argue for individualized assessments that consider age, tumor type, and specific hormone combinations. For breast-cancer survivors, especially younger patients facing cardiovascular and bone-health risks, hormone therapy could offer quality-of-life benefits without necessarily raising recurrence risk. The regulatory shift thus opens a pathway for shared decision-making and precision-medicine approaches in menopause management.
Why it matters
The warning removal may expand safe treatment options for millions of menopausal women, including breast-cancer survivors.
In this story